DescriptionCurator's Comment: Description was created based on several sources including http://www.ncbi.nlm.nih.gov/pubmed/26345206
Curator's Comment: Description was created based on several sources including http://www.ncbi.nlm.nih.gov/pubmed/26345206
Tetraprenylacetone (Geranylgeranylacetone) is an anti-peptic ulcer drug developed and approved in Japan in 1984. Tetraprenylacetone is shown to suppress H. pylori induced tissue and cell injury and inflammatory reaction, so it is expected to show beneficial effects on H. pylori-infected tissues. Tetraprenylacetone is used to treat patients suffering from peptic ulcers and gastritis. In Japan it is sold under the brand name Selbex.
CNS Activity
Sources: http://www.ncbi.nlm.nih.gov/pubmed/24098472
Curator's Comment: GGA (Tetraprenylacetone) is able to pass through blood brain barrier
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: map04210 Sources: http://www.ncbi.nlm.nih.gov/pubmed/27470333 |
|||
Target ID: Chaperone protein DnaK Helicobacter pylori NCTC 11637 ATCC 43504 Sources: http://www.ncbi.nlm.nih.gov/pubmed/26345206 |
0.076 mM [Kd] | ||
Target ID: CHEMBL5460 Sources: http://www.ncbi.nlm.nih.gov/pubmed/26345206 |
0.02 mM [Kd] | ||
Target ID: CHEMBL2157 Sources: http://www.ncbi.nlm.nih.gov/pubmed/15068414 |
|||
Target ID: 682837.0 Gene Symbol: Muc5ac Sources: http://www.ncbi.nlm.nih.gov/pubmed/16240224 |
|||
Target ID: 282586.0 Gene Symbol: Muc6 Sources: http://www.ncbi.nlm.nih.gov/pubmed/16240224 |
|||
Target ID: Hsp70 [Homo sapiens] Sources: http://www.ncbi.nlm.nih.gov/pubmed/17684364 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Selbex Approved UseImprovement of gastric mucosal lesions (erosion, hemorrhage, redness and edema) in the following diseases:
Acute gastritis and acute exacerbation stage of chronic gastritis and Gastric ulcers Launch Date1984 |
|||
| Primary | Selbex Approved UseImprovement of gastric mucosal lesions (erosion, hemorrhage, redness and edema) in the following diseases:
Acute gastritis and acute exacerbation stage of chronic gastritis and Gastric ulcers Launch Date1984 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
246.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17482416/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRAPRENYLACETONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
851.7 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17482416/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRAPRENYLACETONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
3.38 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17482416/ |
50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRAPRENYLACETONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
100 mg 3 times / day multiple, oral Highest studied dose Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: |
|
50 mg 3 times / week multiple, oral Studied dose Dose: 50 mg, 3 times / week Route: oral Route: multiple Dose: 50 mg, 3 times / week Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Disc. AE: Angina pectoris... AEs leading to discontinuation/dose reduction: Angina pectoris (1.3%) Sources: |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Angina pectoris | 1.3% Disc. AE |
50 mg 3 times / week multiple, oral Studied dose Dose: 50 mg, 3 times / week Route: oral Route: multiple Dose: 50 mg, 3 times / week Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Sample Use Guides
Capsules 50 mg:
The usual adult dosage for oral use is 3 capsules (150 mg
of teprenone) daily in three divided doses after meals.
The dosage may be adjusted depending on the patient’s
age and symptoms.
Fine Granules 10%:
The usual adult dosage for oral use is 1.5 g (150 mg of
teprenone) daily in three divided doses after meals. The
dosage may be adjusted depending on the patient’s age
and symptoms.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/27470333
Human melanoma cell lines G361, SK-MEL-2, and SK-MEL-5 were treated with GGA (Tetraprenylacetone) at various doses (1-100uM). GGA significantly reduced the viability of G361, SK-MEL-2, and SK-MEL-5 human melanoma cells at concentrations above 10uM.
| Substance Class |
Mixture
Created
by
admin
on
Edited
Mon Mar 31 18:27:37 GMT 2025
by
admin
on
Mon Mar 31 18:27:37 GMT 2025
|
| Record UNII |
S8S8451A4O
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
FDA ORPHAN DRUG |
743920
Created by
admin on Mon Mar 31 18:27:37 GMT 2025 , Edited by admin on Mon Mar 31 18:27:37 GMT 2025
|
||
|
FDA ORPHAN DRUG |
742220
Created by
admin on Mon Mar 31 18:27:37 GMT 2025 , Edited by admin on Mon Mar 31 18:27:37 GMT 2025
|
||
|
FDA ORPHAN DRUG |
744620
Created by
admin on Mon Mar 31 18:27:37 GMT 2025 , Edited by admin on Mon Mar 31 18:27:37 GMT 2025
|
||
|
NCI_THESAURUS |
C29701
Created by
admin on Mon Mar 31 18:27:37 GMT 2025 , Edited by admin on Mon Mar 31 18:27:37 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5412
Created by
admin on Mon Mar 31 18:27:37 GMT 2025 , Edited by admin on Mon Mar 31 18:27:37 GMT 2025
|
PRIMARY | |||
|
31649
Created by
admin on Mon Mar 31 18:27:37 GMT 2025 , Edited by admin on Mon Mar 31 18:27:37 GMT 2025
|
PRIMARY | |||
|
Teprenone
Created by
admin on Mon Mar 31 18:27:37 GMT 2025 , Edited by admin on Mon Mar 31 18:27:37 GMT 2025
|
PRIMARY | |||
|
S8S8451A4O
Created by
admin on Mon Mar 31 18:27:37 GMT 2025 , Edited by admin on Mon Mar 31 18:27:37 GMT 2025
|
PRIMARY | |||
|
100000077558
Created by
admin on Mon Mar 31 18:27:37 GMT 2025 , Edited by admin on Mon Mar 31 18:27:37 GMT 2025
|
PRIMARY | |||
|
m10566
Created by
admin on Mon Mar 31 18:27:37 GMT 2025 , Edited by admin on Mon Mar 31 18:27:37 GMT 2025
|
PRIMARY | Merck Index | ||
|
S8S8451A4O
Created by
admin on Mon Mar 31 18:27:37 GMT 2025 , Edited by admin on Mon Mar 31 18:27:37 GMT 2025
|
PRIMARY | |||
|
C66587
Created by
admin on Mon Mar 31 18:27:37 GMT 2025 , Edited by admin on Mon Mar 31 18:27:37 GMT 2025
|
PRIMARY | |||
|
SUB15486MIG
Created by
admin on Mon Mar 31 18:27:37 GMT 2025 , Edited by admin on Mon Mar 31 18:27:37 GMT 2025
|
PRIMARY | |||
|
CHEMBL79686
Created by
admin on Mon Mar 31 18:27:37 GMT 2025 , Edited by admin on Mon Mar 31 18:27:37 GMT 2025
|
PRIMARY | |||
|
1362746
Created by
admin on Mon Mar 31 18:27:37 GMT 2025 , Edited by admin on Mon Mar 31 18:27:37 GMT 2025
|
PRIMARY | RxNorm | ||
|
2596
Created by
admin on Mon Mar 31 18:27:37 GMT 2025 , Edited by admin on Mon Mar 31 18:27:37 GMT 2025
|
PRIMARY | |||
|
6809-52-5
Created by
admin on Mon Mar 31 18:27:37 GMT 2025 , Edited by admin on Mon Mar 31 18:27:37 GMT 2025
|
PRIMARY | |||
|
DTXSID6048620
Created by
admin on Mon Mar 31 18:27:37 GMT 2025 , Edited by admin on Mon Mar 31 18:27:37 GMT 2025
|
PRIMARY |
All of the following components must be present:
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |